Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 16/20 | 0.86 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.74 |
| ▸ | HTR6 | P50406 | 12/20 | 0.73 |
| ▸ | DRD2 | P14416 | 5/20 | 0.72 |
| ▸ | KDM1A | O60341 | 3/20 | 0.52 |
| ▸ | KDM1B | Q8NB78 | 3/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3323948 | 0.99 | DRD3 (0.84) | DRD3HRH3HTR6DRD2KDM1A | |
| SCHEMBL3326267 | 0.81 | HTR6 (0.78) | DRD3HRH3HTR6DRD2KDM1A | |
| SCHEMBL3328910 | 0.81 | DRD3 (0.58) | DRD3HRH3HTR6DRD2KDM1A | |
| Hydrochloric Acid SCHEMBL3327343 | 0.80 | DRD3 (0.58) | DRD3HRH3HTR6DRD2KDM1A | |
| SCHEMBL394561 | 0.77 | DRD3 (0.63) | DRD3HRH3HTR6DRD2 | |
| SCHEMBL29682956 | 0.76 | KDM1A (0.69) | DRD3HRH3HTR6KDM1AKDM1B | |
| SCHEMBL20656913 | 0.76 | KDM1A (0.69) | DRD3HRH3HTR6KDM1AKDM1B | |
| SCHEMBL19725487 | 0.76 | KDM1A (0.69) | DRD3HRH3HTR6KDM1AKDM1B | |
| SCHEMBL21114544 | 0.76 | KDM1A (0.70) | DRD3HRH3HTR6DRD2KDM1A | |
| SCHEMBL19725455 | 0.76 | KDM1A (0.70) | DRD3HRH3HTR6DRD2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507469-B2 | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-08-13 | — | — | US | claimed |
| US-20100137280-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-06-03 | — | — | US | claimed |
| US-8507469-B2 | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-08-13 | — | — | US | disclosed |
| US-20100137280-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137280-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR4, HTR3C | DRD3 35/4885HRH3 110/4885HTR6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.